NASDAQ:IMTX Immatics Q1 2026 Earnings Results & Report $7.14 +0.14 (+2.00%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$6.94 -0.20 (-2.79%) As of 10/15/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immatics missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$0.50 versus the -$0.42 consensus estimate, while revenue of $8.81 million fell short of the $9.79 million estimate by $0.98 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Immatics EPS ResultsActual EPS-$0.50Consensus EPS -$0.42Beat/MissMissed by -$0.08One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersImmatics Revenue ResultsActual Revenue$8.81 millionExpected Revenue$9.79 millionBeat/MissMissed by -$981.82 thousandYoY Revenue GrowthN/AUpcoming EarningsImmatics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Immatics Q1 2026 Earnings FAQ Did Immatics beat earnings estimates for Q1 2026? Immatics (NASDAQ:IMTX) reported earnings of -$0.50 per share for Q1 2026, missing the consensus estimate of -$0.42. The report was announced on Tuesday, May 12, 2026. What was Immatics' revenue for Q1 2026? Immatics reported revenue of $8.81 million for Q1 2026, against a consensus estimate of $9.79 million. When is Immatics' next earnings date? Immatics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immatics on the company's earnings history page. Immatics Earnings HeadlinesStifel initiates coverage of Immatics NV at buyOctober 14 at 12:52 AM | msn.comImmatics (NASDAQ:IMTX) Sets New 12-Month Low - Here's What HappenedOctober 9, 2026 | americanbankingnews.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system. | Banyan Hill Publishing (Ad)Financial Review: Exicure (NASDAQ:XCUR) versus Immatics (NASDAQ:IMTX)October 6, 2026 | americanbankingnews.comImmatics and 4 more stocks see action from activist investorsSeptember 4, 2026 | msn.comImmatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer ProgramsAugust 26, 2026 | tipranks.comSee More Immatics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email. Email Address About ImmaticsImmatics (NASDAQ:IMTX) (NASDAQ: IMTX) is a biotechnology company focused on developing T cell receptor (TCR)-based therapies for the treatment of cancer. The company identifies cancer targets and designs treatments intended to direct a patient’s immune system toward tumor cells, including solid tumors that may be difficult to address with conventional immunotherapies. Immatics’ technology platforms support several therapeutic approaches, including TCR-engineered T-cell therapies and TCR-based bispecific molecules that can engage both cancer targets and T cells. Its product pipeline has included candidates directed at targets such as PRAME, a tumor-associated antigen expressed in multiple cancers. The company also uses its target-discovery and validation platforms to identify and evaluate cancer antigens for potential drug development. Founded in 2000 and headquartered in Tübingen, Germany, Immatics has expanded its operations internationally, including a presence in the United States. The company develops therapies independently and through collaborations with pharmaceutical and biotechnology partners. Immatics is led by Chief Executive Officer Harpreet Singh, who has been associated with the company since its early development.View Immatics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
